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1. Introduction  
The global impact of renal cell carcinoma (RCC) cannot be overemphasized. Approximately 
111,100 new cases and 43,000 deaths from the disease among men in developed countries 
occurred in 2008 alone (Jemal et al. 2011). In 2010, RCC ranked as the seventh and eighth 
most common malignancy in men and women in the United States, respectively, with 58,240 
new cases and 13,040 deaths expected (Jemal et al. 2010). The incidence of renal cancer has 
been steadily increasing over the last two decades (Chow et al. 1999; Hock et al. 2002).  
Surgical extirpation is considered the gold standard for the treatment of an enhancing renal 
mass. This has traditionally been performed via radical nephrectomy (RN), in which the 
entire kidney is removed along with the renal mass. While it is possible to maintain normal 
renal function after a radical nephrectomy, a growing body of evidence demonstrates that 
there is an increasing incidence of morbidity and mortality associated with decreasing renal 
function. This realization has refocused attention on the importance of partial nephrectomy 
in the management of renal masses.  
Although most of the world literature reports on the utilization of and the outcomes of 
sporadic RCCs, the familial renal cancer patients managed at the National Cancer Institute 
(NCI) provide a robust data set allowing for examination of the oncologic and renal 
functional outcomes of numerous clinical scenarios and technical approaches, such as initial, 
repeat, and salvage partial nephrectomies, as well as renal interventions performed via 
open, laparoscopic, or robotic approaches. While performing serial interventions on the 
same renal unit results in greater morbidity with each subsequent surgery, metastasis-free 
survival and renal replacement therapy-free survival are high, making re-operative renal 
surgery a reasonable option for selected patients. We now advocate that the amount of 
preservable renal parenchyma, rather than tumor size, be the main determinant of the 
feasibility of partial nephrectomy (Lane, Fergany, Linehan and Bratslavsky, 2010). 
In addition to discussing the importance of surgical preservation of renal function via partial 
nephrectomy and its role in avoiding the morbidity and costs of renal replacement therapy 
(RRT), data will also be provided about emerging approaches to nephron-sparing surgery 
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(NSS). While open partial nephrectomy (OPN), in which only the renal mass is removed 
sparing the unaffected renal parenchyma, had been the only viable treatment option, 
advances in laparoscopic and robotic surgery have allowed for a minimally invasive 
approach to renal surgery that speeds convalescence and decreases the pain associated with 
the procedure.  
In summary, this chapter will provide the rationale and oncologic and functional outcomes 
that support an aggressive approach towards maximal renal preservation. 
2. Oncologic outcomes 
2.1 Open partial nephrectomy 
Current treatment guidelines issued by both the American Urological Association (AUA) 
and the European Association of Urology (EAU) recognize NSS as the preferred treatment 
for renal masses up to 7cm in size (Campbell et al. 2009; Ljungberg et al. 2010). While 
minimally invasive options such as laparoscopic partial nephrectomy (LPN) and robotic 
assisted partial nephrectomy (RAPN) are gaining in popularity, OPN provides unique 
advantages that have not yet been replicated by other approaches, such as the ability to use 
cold ischemia and non-hilar clamping to maintain a bloodless operative field (Margreiter 
and Marberger 2010; Volpe et al. 2011). There is robust data describing the oncologic efficacy 
of open partial nephrectomy (Becker et al. 2006; Becker et al. 2006; Fergany et al. 2006; 
Pahernik et al. 2006). (Table 1) 
 
Author 
(Year) 
No. of 
patients
Mean 
tumor size 
(cm) 
5-yr CSS 
(%) 
10-yr CSS 
(%) 
Local 
recurrence 
(%) 
Mean Follow-
up 
(mo) 
Pahernik et 
al (2006) 715 3 98.5 96.7 3.3 79 
Becker et al 
(2006) 241 3.7 97.8 95.8 1.4 66 
Fergany et al 
(2006) 400 4.2 82 – 4 62 
Becker et al 
(2006) 69 5.3 100 100 5.8 74 
Table 1. Oncologic Outcomes of Contemporary OPN Series 
OPN for renal masses less than 4cm in size has been shown to be oncologically equivalent to 
radical nephrectomy. Belldegrun and colleagues compared 146 subjects who underwent 
OPN to 125 matched subjects treated with total nephrectomy and found that there was no 
difference in cancer-specific survival at nearly five years of follow-up (Belldegrun et al. 
2008). Similarly, when comparing the cancer-specific mortality for OPN vs. radical 
nephrectomy in 1454 subjects treated for tumors up to 4cm at seven international academic 
centers, there was no statistically significant difference between the two approaches at an 
average follow-up of slightly more than five years (2.2% for OPN vs. 2.6% for radical 
nephrectomy; p = 0.8) (Patard et al. 2004).  
Most recently, the results of the prospective, randomized EORTC phase III trial comparing 
the oncologic outcomes of elective NSS vs. radical nephrectomy for renal tumors up to 5cm 
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were reported (Van Poppel et al. 2011). From 1992-2003, 541 subjects with normal 
contralateral renal units were enrolled and followed for a median of 9.3 years after surgery 
(RN = 273, NSS = 268). While this trial was closed early because of poor accrual, the overall 
survival rates of 81.1% for RN and 75.7% for NSS were observed. This difference was not 
statistically significant when analysis was limited to clinically and pathologically eligible 
subjects (P=0.175). Similarly, there was no significant difference in time to progression 
between RN and NSS (P=0.48). Cancer-specific survival was not a study endpoint and only 
12 of 117 subject deaths were attributable to RCC (4 in the RN group and 8 in the NSS 
group).  
Urologic oncologists continued to expand the “classic” non-essential indications for OPN to 
routinely include tumors up to 7cm in size (Russo et al. 2002; Russo 2007; Lane et al. 2010). 
Leibovich and colleagues retrospectively compared 91 subjects who underwent PN for tumors 
ranging from 4-7cm to 841 subjects treated with radical nephrectomy at the Mayo Clinic from 
1970-2000 (Leibovich et al. 2004). At 5 years of follow-up, there were no statistically significant 
differences in cancer-specific survival and metastasis-free survival between these two groups. 
Dash and colleagues from Memorial Sloan-Kettering Cancer Center compared elective OPN 
compared elective OPN (n=45) to radical nephrectomy (n=151) in subjects with clear cell RCC 
tumors ranging between 4-7cm (Dash et al. 2006). They reported identical disease-free survival 
at 21 months of follow-up, however, the 5% recurrence rate seen in the OPN cohort prompted 
the authors to recommend that patients with T1b lesions managed with NSS be surveilled for 
an extended period of time. 
2.1.1 Open partial nephrectomy for local recurrence 
Obtaining a negative surgical margin is a critical objective in NSS. The size of the negative 
margin needed to maintain oncologic efficacy is small and the attainment of wide margins 
comes directly at the cost of preserved renal parenchyma (Sutherland et al. 2002). 
Enucleative surgery for well encapsulated tumors, in which no margin of normal 
parenchyma is excised, may also be a reasonable approach, especially in patients with 
significant pre-operative renal insufficiency or multifocal disease. This surgical approach 
does not appear to hamper survival outcomes compared to PNs in which a margin is taken 
(Carini et al. 2006; Carini et al. 2006; Minervini et al. 2011). 
While surgical site recurrence rates are low and typically associated with grossly positive 
surgical margins at the time of NSS, the management of locally recurrent disease, or 
metachronous multifocal disease in the ipsilateral renal unit, is challenging and often well 
suited to OPN (Russo 2007). The NCI experience of managing familial renal cancer 
syndromes such as von Hippel-Lindau (VHL), hereditary papillary renal carcinoma 
(HPRC), and Birt-Hogg-Dube’ (BHD) provides unique insight into the management of 
locally recurrent RCC (Singer and Bratslavsky 2010).  
In order to preserve renal function, maximize the time interval between repeat partial 
nephrectomies, and minimize the risk of metastasis, the NCI employs the “3cm rule” as a 
size threshold for surgical decision making. When the largest solid tumor in a given kidney 
measures 3cm in diameter NSS is recommended via enucleation of all detectable lesions 
within that renal unit (Walther et al. 1999; Duffey et al. 2004). It should be noted, however, 
that the 3cm rule was initially developed in patients with VHL and then applied to patients 
with HPRC and BHD. Patients with hereditary leiomyomatosis and renal cell carcinoma 
(HLRCC), which is associated with papillary type 2 tumors that are known for their 
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virulence and early metastatic potential, are never observed if solid renal tumor is detected. 
These patients are offered surgical extirpation that includes a margin of normal parenchyma 
as soon as a solid solid lesion is detected. 
Re-operative NSS requires a careful balance between oncologic efficacy and renal 
preservation. Although there have been significant advances in the use of systemic targeted 
therapies to treat locally advanced and metastatic RCC, these agents are not considered 
curative and are associated with significant toxicities, which highlights the importance of 
timely and effective surgical management for local recurrences (Rini 2009).  
Due to the added surgical challenges and morbidity that re-operative renal surgery entails, 
there are few publications available to guide patients and their oncologists (Novick and Streem 
1992; Steinbach et al. 1995; Ansari et al. 2003). Johnson and colleagues at the NCI reviewed 51 
planned repeat partial nephrectomies in 47 subjects with locally recurrent disease (Johnson et 
al. 2008). A total of 40 perioperative complications occurred. Although the majority of these 
complications did not result in long-term disability, one subject suffered an intraoperative 
myocardial infarction and died postoperatively, and three subjects lost a renal unit. Despite the 
increased degree of perioperative morbidity associated with repeat NSS, only 3 subjects (5.8%) 
in Johnson’s series required RRT; a number that would have been considerably higher if 
radical nephrectomy had been performed, considering that one-third of the surgeries in their 
cohort were performed on a solitary kidney.  
Bratslavsky and colleagues studied a small cohort of subjects who underwent three or more 
surgical interventions on the same renal unit, which they described as “salvage” PN 
(Bratslavsky et al. 2008). Not surprisingly, major perioperative complications occurred in 
46%. However, more than 75% of the renal units were saved with minimal changes in 
postoperative serum creatinine, creatinine clearance, and differential renal function. The 
authors demonstrated that salvage PN was a viable option for select patients with recurrent, 
mulitifocal localized kidney cancer, and for the first time demonstrated the feasibility of 
such procedures, as well as resilience of the kidneys in their ability to survive repeat surgical 
interventions. (Table 2) 
Most recently, Singer and colleagues described the renal functional and oncologic outcomes 
of patients with bilateral renal masses managed surgically at the NCI who had at least 10 
years of post-operative follow-up (Singer et al. 2011). They identified a cohort of 128 subjects 
who had undergone bilateral renal surgery with a median of 3 operations per person. Sixty-
eight percent of the cohort had repeat surgery on the same renal unit, with a median time 
between interventions of 6.2 years. At a median follow-up of 16 years, overall survival was 
88%, RCC-specific survival was 97%, and metastasis-free survival was 88%. Despite 
bilateral, and infrequently repeat interventions, the most recent calculated median eGFR 
was 57 mL/min/1.73m2 for the entire cohort. Greater than 95% of subjects were able to 
avoid RRT. This work has demonstrated that at a minimum of 10 years after initial surgery 
and despite the need for repeat surgical interventions on the same kidney, NSS allows for 
excellent oncologic and functional outcomes in selected patients.  
2.2 Laparoscopic partial nephrectomy 
LPN has gained acceptance as the de facto standard treatment for renal cortical tumors less 
than 4cm in size, when technically feasible by this approach (Lane and Gill 2007; Gong et al. 
2008; Lane and Gill 2010). Initially employed to resect small, exophytic renal masses, the 
indications have expanded to include completely endophytic tumors, hilar tumors and 
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tumors that measure 4–7cm in size (Gill et al. 2006; Permpongkosol et al. 2006; Lattouf et al. 
2008; Simmons et al. 2009; Shikanov et al. 2010). The challenges of LPN, when compared to 
OPN, include completely resecting the tumor in a bloodless field and performing the 
necessary renorrhaphy while simultaneously minimizing warm ischemic time. 
Several of these challenges have been overcome with technical modifications to the surgery 
including magnified visualization, improved tools for intracorporal suturing and cold 
ischemia, as well as improved laparoscopic equipment. 
 
 Johnson et al. (2008) Bratslavsky et al. (2008) 
Partial Nephrectomy Type Repeat Salvage 
Patients, n 47 11 
Partial nephrectomy, n 51 13 
Median tumors removed (range) 7 (1-55) 5 (1-27) 
Median EBL, mL (range) 1,800 (50-21,500) 2,100 (200-12,000) 
Transfusion Requirement (%) 38 (75) 10 (77) 
Median Units Transfused (Range) 2 (0-31) 4.5 (0-18) 
Intraoperative Complications   
Visceral or vascular injury (%) 2 (4) 6 (46) 
Ureteral Injury (%) 1 0 
Postoperative complications   
Prolonged Urine Leak (%) 8 (15) 2 (15) 
Permanent Hemodialysis (%) 3 (6) 2 (15) 
Renal Unit Loss (%) 3 (6) 3 (23) 
Rhabdomyolysis (%) 0 1 (8) 
Reoperation (%) 2 (4) 4 (36) 
Cardiovascular events (%) 1 (2) 0 
Table 2. Repeat and Salvage PN Outcomes 
As urologists gained more experience with LPN, more centers have employed LPN for 
technically challenging scenarios where OPN was historically utilized. Tumors that are 
centrally located and close to the hilum mean the surgeon will encounter larger blood 
vessles and must perform a more extensive renorrhaphy, often with pelvicaliceal repair. 
Nadu and colleagues found that LPN for peripheral (n=159) vs. central (n=53) tumors had 
similar estimated blood loss (EBL) and operative times, whereas WIT was longer for central 
masses (37 vs. 28 min) (Nadu et al. 2009). Richstone and colleagues evaluated their results 
with LPN for hilar tumors in 18 patients and reported a mean operative time of 173 min, 
WIT of 29.4 min and median EBL of 394 ml (Richstone et al. 2008). In addition to tumors in 
difficult locations, PN in the obese patient population have been shown to have a higher rate 
of postoperative complications, such as cardiovascular events, wound infections, DVT and 
wound dehiscence. Romero and colleagues compared LPN (n=56) and OPN (n=28) in an 
obese cohort and demonstrated that the LPN group had shorter operative time, decreased 
EBL and fewer intraoperative and postoperative complications compared to those treated by 
OPN (Romero et al. 2008). 
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With regards to oncologic outcomes when compared with OPN, LPN has proven to have 
equivalent 5 year outcomes for T1a lesions in numerous single institution and multi-
institutional studies (Porpiglia et al. 2005; Permpongkosol et al. 2006; Bollens et al. 2007; Gill 
et al. 2007; Lane and Gill 2007; Marszalek et al. 2009; Simmons et al. 2009). Rassweiler and 
colleagues reported a local recurrence rate of 1.41% among all the urologic malignancies 
treated in 1098 patients who underwent mixed urologic laparoscopic procedures over a ten 
year period with a median follow-up of 5 years (Rassweiler et al. 2003). More recently, the 
Cleveland Clinic reported 5 year survival data after LPN (n=58) with a mean follow-up of 
5.7 years (Lane and Gill 2007). Overall survival was 86% and cancer specific survival was 
100%. They did not report development of metastatic disease and documented a single local 
recurrence (2.7%). These findings were consistent with other reported cancer specific 
survival in reported LPN series which range from 91.4% to 100%.  
The overall local recurrence rate in reported LPN series range from 0% to 2.4% with positive 
surgical margins ranging from 0% to 2.9% (Porpiglia et al. 2005; Lane and Gill 2007; Lane 
and Gill 2010). Simmons and colleagues reported on the eqiuivalence of oncologic outomes 
in select patients with clinical stage T1b–T3 tumors treated with LPN compared to a 
matched cohort of patients who underwent laparoscopic radical nephrectomy (Simmons et 
al. 2009). The cancer specific survival rate in both groups was 97% and the recurrence free 
survival was 97% and 94% in the laparoscopic radical nephrectomy and LPN groups, 
respectively. In a multi-institutional study, Porpiglia and colleagues described LPN for T1b 
masses in 63 patients and reported intraoperative hemorrhage in 7.3% of cases and 
postoperative complications in 14.6% of cases (Porpiglia et al. 2010). (Table 3) 
 
Author (Year) 
No. of 
patients
Mean 
tumor 
size (cm) CSS (%) 
Positive 
Surgical 
Margin (%)
Local 
recurrence 
(%) 
Mean 
Follow-up 
(mo) 
Bollens 
et al (2007) 39 2.3 100 2.6 0 15 
Permpongkosol
et al (2006) 85 2.4 97.6 2.4 1.7 40 
Gill et al (2007) 771 2.7 99.3 1.6 1.4 14 
Marszalek 
et al (2009) 100 2.8 96.3 4 3 44 
Lane et al (2007) 58 2.9 100 1.7 1.7 68 
Simmons 
et al (2009) 35 4.9 97 0 6 44 
Porpiglia 
et al (2010) 63 4.7 N/A 6.5 0 N/A 
Table 3. Oncologic Outcomes of Contemporary LPN Series 
Although comparisons of open and laparoscopic PN have been performed, all studies are 
retrospective, and no randomized studies have been done so far. Nevertheless, the available 
literature suggests the equivalence of LPN to OPN for renal cortical tumors. Gill and 
colleagues in a multi-institutional study compared LPN (n=1029) and OPN (n=771) in 1800 
patients with a renal cortical tumor measuring less than 7cm (Gill et al. 2007). In that study, 
patients undergoing OPN were a higher risk group with decreased performance status, 
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renal functional impairment and more tumors greater than 4cm. The authors reported a 
positive surgical margin rate of 2.85% for LPN versus 1.26% for OPN and three year cancer 
specific survival of 99.3% for LPN and 99.2% for OPN. Marszalek and colleagues performed 
a matched-pair comparison of 200 patients matched for age, sex, and tumor size who 
underwent OPN (n=100) and LPN (n=100) with median 3.6 year follow-up (Marszalek et al. 
2009). The stage of renal cell cancer was pT1 in all cases and the average tumor size was 
2.8cm in the LPN cohort and 2.9cm in the OPN cohort. They reported a positive surgical 
margin rate of 4% and 2% in the LPN and OPN cohorts, respectively. Estimated 5 year local 
recurrence free survival using Kaplan-Meier method was 97% and 98%, and distant 
recurrence free survival was 99% and 96% in the LPN and OPN cohorts, respectively.  
In summary, use of LPN has expanded from its initial use for the extirpation of smaller 
exophytic lesions to larger T1b tumors, endophytic and hilar lesions. It appears that for 
tumors less than 4cm in size, LPN provides equivalent oncologic control to OPN at 
intermediate follow-up. Oncologic outcomes are encouraging for tumors in the 4-7cm range 
although intermediate term oncologic data has yet to be reported.  
2.3 Robotic assisted partial nephrectomy 
With the establishment of LPN as an alternative to OPN in the treatment of renal cortical 
masses, RAPN has been increasingly adopted by urologic surgeons with the goal of 
broadening the utilization of NSS while still providing the advantages of minimally invasive 
surgery. Established advantages of minimally invasive techniques for PN include decreased 
postoperative pain, decreased hospital stay and shorter convalescence compared with 
standard open technique. This alternative to LPN may aid in the learning curve and 
facilitate in the reconstructive aspects of what is a technically demanding operation. 
Features of the robotic platform include stereoscopic vision, articulating instruments, and 
motion scaling to reduce tremor. These amenities may allow the surgeon to replicate 
established maneuvers employed during OPN, allow for extirpation of complex, centrally 
located tumors, and reconstruction of the pelvicaliceal system. 
The feasibility and safety of RAPN has been demonstrated in several small, single institution 
studies (Gettman et al. 2004; Phillips et al. 2005; Caruso et al. 2006; Kaul et al. 2007; Aron et 
al. 2008; Deane et al. 2008; Benway et al. 2009; Ho et al. 2009; Michli and Parra 2009; Benway 
et al. 2010). Recent studies have demonstrated the feasibility of RAPN for larger, deeper 
tumors that are hilar in their location as well as for multiple tumors in the hereditary renal 
cancer population (Rogers et al. 2008; Boris et al. 2009; Gupta et al. 2011). (Table 4)  
In a recent review of the RAPN literature, Shapiro and colleagues analyzed the results of the 
largest series of RAPN and reported an overall positive surgical margin rate of 3.3% (7/211) 
and that at up to 54 months of follow-up, there were no local or distant recurrences (Shapiro 
et al. 2009). With the expansion of LPN to T1b tumors, RAPN has also been employed for 
these challenging tumors. Patel and colleagues retrospectively analyzed a cohort of 71 
patients who underwent RAPN for tumors greater than 4cm (n=15) compared to those with 
tumors less than 4cm (N=56) (Patel et al. 2010). There were no positive surgical margins in 
the greater than 4cm group and 3 reported in the less than 4 cm group for an overall rate of 
5.4% but the authors noted that on final pathology only 1 of the positive surgical margins 
was for a malignancy with no sequelae at one year. Gupta and colleagues reported on 19 
surgeries for multiple tumors (average 2.3 tumors/kidney) with the largest tumor greater 
than 4cm (Gupta et al. 2010). Remarkably, in this population, no patient required a blood 
transfusion and mean WIT was 36 min. There are currently no intermediate or long term 
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oncologic outcomes reported in the literature for RAPN, but short term outcomes from 
several robotic series seem to be equivalent to those reported for LPN series. However, these 
data are immature at best and long term data is needed regarding oncologic outcomes.  
 
Author 
(Year) 
No. of 
RAPN 
Mean tumor 
size (cm) 
Mean 
WIT 
(min) 
Mean 
operative 
time (min)
Mean 
blood- 
loss 
(ml) 
Positive 
surgical 
margin 
Mean 
Follow-up 
(mo) 
Boris et al 
(2009) 10 2.3 (multiple) 29.6 257 360 
not 
assessed 9 
Scoll et al 
(2010) 98 2.8 25.5 203 127 5 13 
Rogers et 
al (2008) 148 2.8 27.8 197 183 6 7 
Benway et 
al (2010) 183 2.9 23.9 210 131.5 4 16 
Rogers et 
al 2008) 8 3.6 31 192 230 0 3 
Patel et al 
(2010) 15 5 25 275 100 0 7 
Gupta et al 
(2010) 19 5 (multiple) 36 390 500 
not 
assessed 22 
Table 4. Selected RAPN Series 
3. Renal functional outcomes 
While it is intuitive that sparing normal renal parenchyma will impart better overall kidney 
function, the misconception long held is that the sacrifice of normal functioning nephrons 
via radical nephrectomy will not cause serious long term side effects. However, one of the 
most important recent concepts to be recognized is the adverse effects of renal insufficiency 
on compounding medical comorbidities. Although no randomized prospective studies exist 
at this time, retrospective analysis revealed that incremental increases in renal insufficiency 
are associated with incremental increases in all-cause hospitalization, cardiovascular 
morbidity and all-cause mortality (Go et al. 2004). Additionally, several other studies 
demonstrated a close association of renal insufficiency with cardiovascular disease, while 
others have suggested that patients treated with radical nephrectomy had shorter overall 
survival when compared to those treated with PN (Russo and Huang 2008; Huang et al. 
2009). Two studies comparing late renal functional outcomes in over 450 patients 
undergoing radical nephrectomy and PN demonstrated that patients undergoing radical 
nephrectomy were more likely to have serum creatinine levels elevated to more than 2.0 
mg/dL and proteinuria (Lau et al. 2000). A more recent study from the Mayo Clinic 
identified 648 patients treated with radical nephrectomy or PN for tumors less than or equal 
to 4 cm and a normal contralateral kidney (Thompson et al. 2008). Overall survival 
calculated in 327 patients under the age of 65 after controlling for year of surgery, diabetes 
at presentation, Charlson comorbidity score and tumor histology found that radical 
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nephrectomy was significantly associated with an increased risk of death. These results 
strongly indicate that the use of radical nephrectomy for small renal masses is unjustified 
oncologically and that NSS should be selected whenever possible. 
Duration and type of “safe” ischemia has been actively evaluated in recent years. A large 
multi-institutional study evaluated the effects of ischemic time on renal function in patients 
undergoing OPN without ischemia, with warm ischemia, and with cold ischemia. This 
study included patients with solitary kidneys and defined chronic renal insufficiency on the 
basis of serum creatinine. The conclusion of this study was that WIT should be limited to 20 
minutes and cold ischemia time to less than 35 minutes to avoid an increased risk of chronic 
renal insufficiency and acute renal failure (Simmons et al. 2008; Becker et al. 2009). As the 
urologic community has gained experience with LPN and RAPN, WIT has been reduced 
and in several studies it was found comparable to that of OPN. (Table 4) Regardless, until 
prospective data can determine the true safe maximum WIT in regards to renal function, 
every attempt to minimize WIT should be made.  
4. Future directions for partial nephrectomy 
With the establishment that PN for renal tumors up to 7cm is oncologically equivalent to 
radical nephrectomy, urologic oncologists have been expanding the indications for PN to 
include tumors greater than 7cm (T2) and even lesions that penetrate the renal capsule 
(T3a) or have tumor thrombus involving the main renal vein (T3b). Breau and colleagues 
from the Mayo Clinic recently reported their experience treating 69 subjects with 
advanced renal tumors (T2=32, T3a=28, T3b=9) who were compared to a matched cohort 
from their kidney tumor registry (Breau et al. 2010). Cancer-specific and overall death 
rates were similar between the two groups (p=0.489 and p=0.642, respectively), and 
differences in metastatic disease and local recurrence at an average follow-up of 3.2 years 
were not statistically significant (p=0.92 and 0.234, respectively). Renal function, however, 
as measured by serum creatinine, was better preserved in the PN group (9.5% increase vs. 
33% increase; p<0.001).  
Similarly, several small series have been reported in which NSS was used in the 
cytoreductive setting for patients with metastatic disease (Krambeck et al. 2006; Hutterer et 
al. 2007). The majority of these cases were performed on solitary kidneys or in the presence 
of renal insufficiency. Survival was not negatively impacted when compared to historic 
controls who received radical nephrectomy, and renal function was preserved adequately to 
avoid RRT, which will help facilitate access to targeted systemic treatments (Singer et al. 
2010; Singer et al. 2011). Targeted systemic therapy has also been used in the neoadjuvant 
setting to downsize the primary tumor in a solitary kidney so that PN would be technically 
feasible (Shuch et al. 2008).  
In the years ahead, it is unlikely that tumor diameter will be a major determinant for the 
type of renal surgery offered to a patient with a renal mass. Instead of size, the surgeon will 
base his or her recommendation for or against NSS on objective measures of the feasibility of 
a safe and complete resection (Lane et al. 2010). Most recently, Bratslavsky has raised the 
concept of the metastatic potential of renal tumors, in which the development of metastatic 
disease is not prevented by removal of the normal renal parenchyma. He argues against 
arbitrary size cut-offs traditionally used for selection of patients for partial nephrectomy, 
and suggests that maximal preservation of normal parenchyma in patients with largest 
tumors may be even more important, as these patients would be at a higher risk for 
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metastatic disease and could benefit for future adjuvant trials or treatment (Bratslavsky, 
2011). Finally, as urologists continue to report and compare their NSS outcomes, they will 
need to use a new metric, such as the RENAL nephrometry score or the PADUA 
classification, which objectively quantifies the anatomic complexity of a renal mass (Kutikov 
and Uzzo 2009; Ficarra et al. 2009).  
5. Conclusions 
NSS should be considered the preferred therapy for renal tumors whenever it is technically 
feasible via any surgical approach. Patients and their referring physicians should seek out 
high-volume centers and experienced surgeons who have a special interest in NSS. The 
method of PN selected, whether OPN, LPN, or RAPN, matters far less than ensuring that 
the correct operation is performed for the appropriate indications. Since the loss of renal 
function can increase the risk of post-operative morbidity and mortality in numerous ways, 
PN must continue to be the treatment of choice for kidney tumors. PN is the oncologically 
sound and functionally prudent way to manage an increasing number of renal tumors. 
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